Assessing the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
The PATHFINDER Study is a prospective, multi-center study that will evaluate the implementation of GRAIL’s multi-cancer early detection test into clinical practice. GRAIL’s test is designed to detect and localize multiple types of cancer through a single blood draw, with a very low false positive rate.
PATHFINDER is the first time GRAIL’s multi-cancer early detection test will be used to return results to healthcare providers and communicated to participants to help guide appropriate diagnostic workup for more than 50 cancer types. The study will enroll approximately 6,200 participants, and they will be followed for 12 months from the time of their enrollment.
Current Status: Enrolling
GRAIL’s Multi-Cancer Early Detection Test
GRAIL’s investigational test is designed to detect multiple types of cancer through a single blood draw by looking for signals of cancer that may be present. If a signal that may be cancer is detected, the test is designed to identify the location in the body where the signal may be coming from, for example, the pancreas or the lungs. This information is intended to help healthcare providers determine the appropriate test(s) to confirm whether cancer is present.
- Dana Farber Cancer Institute
- Intermountain Healthcare
- Mayo Clinic
- Oregon Health & Science University
- Sutter Health
The PATHFINDER Study is currently open to men and women aged 50 years or older who meet certain eligibility criteria and receive care at select locations of participating health systems. Participants of previous or ongoing GRAIL-sponsored studies are not eligible to participate in the PATHFINDER Study.